A
Athenex Inc
F:2MT
Athenex Inc
F:2MT
Price:
0.12
EUR
Market Closed
Market Cap:
€715.7m
Relative Value
There is not enough data to reliably calculate the relative value of 2MT.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
2MT
Relative Value
Base Case
Not Available
A
Multiples Across Competitors
2MT Competitors Multiples
Athenex Inc Competitors
Athenex Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
A
|
Athenex Inc
F:2MT
|
715.7m EUR | 6.4 | -7 | -10.1 | -9.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
396.8B USD | 6.7 | 169.3 | 16.4 | 23.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
198.7B USD | 5.4 | 25.8 | 14.8 | 14.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
186B USD | 6.4 | 22.9 | 15.6 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.7B USD | 10.1 | 32.3 | 23.8 | 24.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.6B USD | 5.6 | 17.8 | 15.1 | 17.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
89B AUD | 4 | 20.6 | 13.8 | 17.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.4B EUR | 14.3 | 33.7 | 57.5 | 59.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
